[천지일보=홍보영 기자] The new coronavirus infection (Corona 19) antibody treatment drug’Rekironaju’ developed in Korea will be supplied to medical institutions starting this month.
The Central Defense Countermeasure Headquarters (Daebon Bang) announced on the 6th that the government will purchase Celltrion Co.’s Rekkironaju (ingredient name Legdanvimab, CT-P59) for a limited time and supply it to medical institutions from mid-February.
The Ministry of Food and Drug Safety (Ministry of Food and Drug Safety) officially licensed Rekirona, developed by Celltrion the day before, as an antibody treatment for Corona 19. Rekironaju is the first drug developed in Korea to be approved for COVID-19 treatment.
Dae-bon Bang explained that it takes time to prepare the product, and the government directly supplies the treatment for a temporary period, and if a supply system is established between medical institutions and pharmaceutical companies, the inconvenience of use will be minimized.
Rekironaju is administered only to subjects approved by the Ministry of Food and Drug Safety.
The scope of use of the drug was finalized in high-risk patients with mild and moderate severity.
The Ministry of Food and Drug Safety has designated patients with mild symptoms and pneumonia who require oxygen therapy, who are 60 years of age or older, have one or more chronic diseases of the cardiovascular system, chronic respiratory tract disease, diabetes, and hypertension.
In each medical institution, these patients can use Rekirona within 7 days of the onset of symptoms.
‘;
Copyright © Cheonji Ilbo-Unauthorized reproduction and redistribution of the Press for New Era